Curtis R Brandt

List of Publications by Year
in descending order

79 papers	1,999 citations	270111 25 h-index	340414 39 g-index
80 all docs	80 docs citations	80 times ranked	2172 citing authors

#	Article	IF	Citations
1	Knockdown of TRIM5Î± or TRIM11 increases lentiviral vector transduction efficiency of human Muller cells. Experimental Eye Research, 2021, 204, 108436.	1.2	3
2	Genomic nucleotide-based distance analysis for delimiting old world monkey derived herpes simplex virus species. BMC Genomics, 2020, 21, 436.	1.2	5
3	Genomic, Recombinational and Phylogenetic Characterization of Global Feline Herpesvirus 1 Isolates. Virology, 2018, 518, 385-397.	1.1	21
4	Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons. Journal of Neuroimmunology, 2018, 322, 26-35.	1.1	9
5	Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork. , 2018, 59, 298.		8
6	Ocular Immunopathology. Molecular and Integrative Toxicology, 2017, , 695-762.	0.5	5
7	Phylogenetic and recombination analysis of the herpesvirus genus varicellovirus. BMC Genomics, 2017, 18, 887.	1.2	31
8	Quantitative Trait Locus Based Virulence Determinant Mapping of the HSV-1 Genome in Murine Ocular Infection: Genes Involved in Viral Regulatory and Innate Immune Networks Contribute to Virulence. PLoS Pathogens, 2016, 12, e1005499.	2.1	30
9	Mapping Murine Corneal Neovascularization and Weight Loss Virulence Determinants in the Herpes Simplex Virus 1 Genome and the Detection of an Epistatic Interaction between the UL and IRS/US Regions. Journal of Virology, 2016, 90, 8115-8131.	1.5	17
10	Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis. Experimental Eye Research, 2016, 148, 12-23.	1.2	7
11	Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit. Journal of Ocular Biology, 2016, 4, .	1.5	5
12	A Mouse Model of Multi-Drug Resistant Staphylococcus aureus-induced Ocular Disease. Journal of Ocular Biology, 2016, 4, .	1.5	2
13	Viral Vector Effects on Exoenzyme C3 Transferaseâ€"Mediated Actin Disruption and on Outflow Facility. , 2015, 56, 2431.		12
14	Genomic, Phylogenetic, and Recombinational Characterization of Herpes Simplex Virus 2 Strains. Journal of Virology, 2015, 89, 6427-6434.	1.5	45
15	Recombination Analysis of Herpes Simplex Virus 1 Reveals a Bias toward GC Content and the Inverted Repeat Regions. Journal of Virology, 2015, 89, 7214-7223.	1.5	44
16	Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps. Antiviral Research, 2014, 109, 83-96.	1.9	7
17	Prospects for Lentiviral Vector Mediated Prostaglandin F Synthase Gene Delivery in Monkey Eyes<i>In vivo</i>. Current Eye Research, 2014, 39, 859-870.	0.7	20
18	Peptide Therapeutics for Treating Ocular Surface Infections. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 691-699.	0.6	21

#	Article	IF	Citations
19	A Cationic Peptide, TAT-Cd0, Inhibits Herpes Simplex Virus Type 1 Ocular Infection In Vivo. , 2013, 54, 1070.		20
20	Using HSV-1 Genome Phylogenetics to Track Past Human Migrations. PLoS ONE, 2013, 8, e76267.	1.1	76
21	Ocular Distribution, Spectrum of Activity, and <i>In Vivo</i> Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application. Antimicrobial Agents and Chemotherapy, 2012, 56, 1390-1402.	1.4	16
22	Antiviral activity of the EB peptide against zoonotic poxviruses. Virology Journal, 2012, 9, 6.	1.4	15
23	Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine, 2011, 29, 7696-7703.	1.7	22
24	Multiplex Sequencing of Seven Ocular Herpes Simplex Virus Type-1 Genomes: Phylogeny, Sequence Variability, and SNP Distribution. , 2011, 52, 9061.		38
25	Identification of the Minimal Active Sequence of an Anti-Influenza Virus Peptide. Antimicrobial Agents and Chemotherapy, 2011, 55, 1810-1813.	1.4	20
26	Sequence Variation in the Herpes Simplex Virus US1 Ocular Virulence Determinant. , 2011, 52, 4630.		10
27	Evaluation of Therapeutic Interventions for Vaccinia Virus Keratitis. Journal of Infectious Diseases, 2011, 203, 683-690.	1.9	28
28	A Quantitative Rabbit Model of Vaccinia Keratitis. , 2010, 51, 4531.		39
29	The Virucidal EB Peptide Protects Host Cells from Herpes Simplex Virus Type 1 Infection in the Presence of Serum Albumin and Aggregates Proteins in a Detergent-Like Manner. Antimicrobial Agents and Chemotherapy, 2010, 54, 4275-4289.	1.4	9
30	A Cationic TAT Peptide Inhibits Herpes Simplex Virus Type 1 Infection of Human Corneal Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 541-547.	0.6	4
31	Multiple Peptides Homologous to Herpes Simplex Virus Type 1 Glycoprotein B Inhibit Viral Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 987-996.	1.4	48
32	Gene Therapy Targeting Glaucoma: Where Are We?. Survey of Ophthalmology, 2009, 54, 472-486.	1.7	36
33	Induction of interleukin-6 in human retinal epithelial cells by an attenuated Herpes simplex virus vector requires viral replication and NFÎºB activation. Experimental Eye Research, 2008, 86, 178-188.	1.2	10
34	Inhibition of Herpes Simplex Virus Type 1 Infection by Cationic Î²-Peptides. Antimicrobial Agents and Chemotherapy, 2008, 52, 2120-2129.	1.4	31
35	Progress and Prospects in Ocular Gene Therapy. , 2008, , 393-420.		0
36	H-1152 Effects on Intraocular Pressure and Trabecular Meshwork Morphology of Rat Eyes. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 373-379.	0.6	27

#	Article	IF	Citations
37	Glaucoma gene therapy. Expert Review of Ophthalmology, 2007, 2, 227-236.	0.3	4
38	Sialic Acid on Herpes Simplex Virus Type 1 Envelope Glycoproteins Is Required for Efficient Infection of Cells. Journal of Virology, 2007, 81, 3731-3739.	1.5	27
39	Addition of a C-Terminal Cysteine Improves the Anti-Herpes Simplex Virus Activity of a Peptide Containing the Human Immunodeficiency Virus Type 1 TAT Protein Transduction Domain. Antimicrobial Agents and Chemotherapy, 2007, 51, 1596-1607.	1.4	23
40	Influenza defense: expanding our arsenal with peptide antivirals. Future Virology, 2007, 2, 231-233.	0.9	1
41	Evaluation of a Î¸-Defensin in a Murine Model of Herpes Simplex Virus Type 1 Keratitis. , 2007, 48, 5118.		43
42	Ocular drug delivery: Molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-454.	0.4	8
43	Ocular drug delivery: molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-454.	0.4	13
44	Ocular drug delivery: molecules, cells, and genes. Canadian Journal of Ophthalmology, 2007, 42, 447-54.	0.4	6
45	Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells. Journal of Virology, 2006, 80, 11960-11967.	1.5	143
46	Corneal Toxicity of Cell-Penetrating Peptides That InhibitHerpes simplexVirus Entry. Journal of Ocular Pharmacology and Therapeutics, 2006, 22, 279-289.	0.6	27
47	The role of viral and host genes in corneal infection with herpes simplex virus type 1. Experimental Eye Research, 2005, 80, 607-621.	1.2	71
48	The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Molecular Vision, 2005, 11, 1112-21.	1.1	65
49	Enhanced isolation of low frequency herpes simplex virus recombinants using green-fluorescent protein and FACS. Journal of Virological Methods, 2004, 115, 73-81.	1.0	2
50	Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model. Current Eye Research, 2004, 29, 167-172.	0.7	5
51	Virulence genes in herpes simplex virus type 1 corneal infection. Current Eye Research, 2004, 29, 103-117.	0.7	11
52	Rapid in vivo isolation of gene expression elements using an HSV amplicon system. Journal of Virological Methods, 2003, 113, 1-12.	1.0	2
53	Tyrosine 116 of the Herpes Simplex Virus Type 1 IEÎ±22 Protein Is an Ocular Virulence Determinant and Potential Phosphorylation Site. , 2003, 44, 4601.		16
54	Multiple Determinants Contribute to the Virulence of HSV Ocular and CNS Infection and Identification of Serine 34 of the US1 Gene as an Ocular Disease Determinant. , 2003, 44, 2657.		27

#	Article	IF	Citations
55	Peptides Containing Membrane-transiting Motifs Inhibit Virus Entry. Journal of Biological Chemistry, 2002, 277, 36018-36023.	1.6	38
56	Transformation of human trabecular meshwork cells with SV40 TAg alters promoter utilization. Current Eye Research, 2002, 25, 347-353.	0.7	9
57	In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. Investigative Ophthalmology and Visual Science, 2002, 43, 151-61.	3.3	94
58	Gene therapy for glaucoma: treating a multifaceted, chronic disease. Investigative Ophthalmology and Visual Science, 2002, 43, 2513-8.	3.3	32
59	Modified FGF4 Signal Peptide Inhibits Entry of Herpes Simplex Virus Type 1. Journal of Virology, 2001, 75, 2634-2645.	1.5	44
60	HSV-1 Vector-Delivered FGF2 to the Retina Is Neuroprotective but Does Not Preserve Functional Responses. Molecular Therapy, 2001, 3, 746-756.	3.7	39
61	Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom Rozites caperata. Antiviral Research, 1999, 43, 67-78.	1.9	53
62	Herpes Simplex Virus Mediated Gene Transfer to Primate Ocular Tissues. Experimental Eye Research, 1999, 69, 385-395.	1.2	58
63	Treatment of Spontaneously Arising Retinoblastoma Tumors in Transgenic Mice with an Attenuated Herpes Simplex Virus Mutant. Virology, 1997, 229, 283-291.	1.1	14
64	Thymidine Kinase and Susceptibility to Interferon Are Not Involved in the Increased Virulence of Recombinant Viruses Isolated following Mixed Ocular Infection with HSV Strains 0D4 and CJ394. Ophthalmic Research, 1996, 28, 125-129.	1.0	1
65	The effect of viral inoculum level and host age on disease incidence, disease severity, and mortality in a murine model of ocular HSV-1 infection. Current Eye Research, 1995, 14, 145-152.	0.7	24
66	Evidence for an Interaction of Herpes Simplex Virus with Chondroitin Sulfate Proteoglycans during Infection. Virology, 1995, 208, 531-539.	1.1	89
67	IFN-Î± induces MxA gene expression in cultured human corneal fibroblasts. Experimental Eye Research, 1995, 60, 137-142.	1.2	8
68	Renin mRNA is synthesized locally in rat ocular tissues. Current Eye Research, 1994, 13, 755-763.	0.7	35
69	Rapid small-scale isolation of herpes simplex virus DNA. Journal of Virological Methods, 1994, 48, 189-196.	1.0	19
70	Ribonucleotide Reductase and the Ocular Virulence of Herpes Simplex Virus Type 1. Frontiers of Virology, 1994, , 136-150.	0.6	1
71	The HSV-1 UL45 18 kDa gene product is a true late protein and a component of the virion. Virus Research, 1993, 29, 167-178.	1.1	48
72	Interferon-Î± and Interferon-Î³ Induced Modulation of Proteins in Human Corneal Fibroblasts. Journal of Interferon Research, 1993, 13, 289-294.	1.2	4

#	Article	IF	Citations
73	Heterogeneity of Type I Collagen Expression in Human Corneal Keratoconus Fibroblasts. Ophthalmic Research, 1993, 25, 273-279.	1.0	5
74	Enhanced Inhibition of Herpes Simplex Virus Type 1 Growth in Human Corneal Fibroblasts by Combinations of Interferon-Â and -Â. Journal of Infectious Diseases, 1992, 166, 1401-1402.	1.9	27
75	Susceptibility of +/+, +/nu and nu/nu BALB/c Mice to Ocular Herpes simplex Virus Infection. Ophthalmic Research, 1992, 24, 332-337.	1.0	7
76	A murine model of herpes simplex virus-induced ocular disease for antiviral drug testing. Journal of Virological Methods, 1992, 36, 209-222.	1.0	34
77	Mixed ocular infections identify strains of herpes simplex virus for use in genetic studies. Journal of Virological Methods, 1991, 35, 127-135.	1.0	8
78	The HSV-1 UL45 gene product is not required for growth in vero cells. Virology, 1991, 185, 419-423.	1.1	46
79	Plasmid mediated mutagenesis of a cellular gene in transfected eukaryotic cells. Nucleic Acids Research, 1987, 15, 561-573.	6.5	25